Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
04/21/2017 04/24/2017 04/25/2017 04/26/2017 04/27/2017 Date
1.02(c) 1.04(c) 1(c) 0.995(c) 0.9999(c) Last
1 207 576 1 394 561 1 564 235 1 002 370 849 377 Volume
+2.00% +1.96% -3.85% -0.50% +0.49% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 7,88x
Capi. / Sales2014 3,47x
Capitalization 124 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
04/25 PROTALIX BIOTHERAPEUTICS : Announces New Preclinical Results Demonstrating a Pos..
04/25 PROTALIX BIOTHERAPEUTICS : Announces Positive Results from Phase II Clinical Tri..
04/19 PROTALIX BIOTHERAPEUTICS : Announces New Preclinical Results Demonstrating a Pos..
04/18 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Other Events
04/18 PROTALIX BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
04/18 Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Po..
04/14 PROTALIX BIOTHERAPEUTICS : plunges after cystic fibrosis trial
04/12 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Submission of Matters t..
04/12 PROTALIX BIOTHERAPEUTICS, INC. : Submission of Matters to a Vote of Security Hol..
04/12 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Other Events
More news
Sector news : Biotechnology & Medical Research - NEC
09:15a REGENERON PHARMACEUTICALS : Genzyme, CHC lift Sanofi's first-quarter figures, up..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 545%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTI..124.72%124
INCYTE CORPORATION23.84%25 403
QUINTILES IMS HOLDINGS..10.03%19 742
LONZA GROUP AG19.57%12 017
SEATTLE GENETICS, INC.29.35%9 736
CELLTRION, INC.--.--%9 610
More Results